CME INFORMATION

TARGET AUDIENCE: Medical Oncologists

GLOBAL LEARNING OBJECTIVES:

Upon completion of this activity, participants should be able to:

• Counsel women with low-risk invasive breast cancer about the absolute risks and benefits of adjuvant systemic therapy.
• Evaluate the emerging data on various adjuvant chemotherapy approaches, including dose-dense treatment and the use of taxanes, and explain the relevance to patients considering adjuvant chemotherapy regimens.
• Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of adjuvant aromatase inhibitors and about switching or sequencing aromatase inhibitors after tamoxifen.
• Develop and explain a management strategy for treatment of premenopausal women with primary breast cancer in the adjuvant setting.
• Develop and explain a management strategy for the treatment of women with HER2-positive primary breast cancer with regard to the use of neoadjuvant and/or adjuvant trastuzumab.

EVALUATION STATEMENT: An evaluation will be given to each participant at the conclusion of this educational activity.

ACCREDITATION STATEMENT: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Research To Practice designates this educational activity for a maximum of 2.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

DISCLOSURE POLICY: As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

COMMERCIAL SUPPORT: This event is supported by an education grant from AstraZeneca Pharmaceuticals LP.